Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone

British Journal of Clinical Pharmacology

Volumn 42, Issue 5, 1996, Pages 589-597

  Hussein, Z ^a,c   Eaves, C J ^a   Hutchinson, D B ^a   Canfield, C J ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Pharmaceutical Systems Inc   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

malaria; NONMEM; P. falciparum; pharmacokinetics; population; proguanil

Indexed keywords

ATOVAQUONE; PROGUANIL;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PLASMODIUM FALCIPARUM; POPULATION; PRIORITY JOURNAL; RACE DIFFERENCE;

EID: 0029807319     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.1996.tb00114.x     Document Type: Article

References (15)

1. Wyler DJ. Malaria-resurgence, resistance and research. N Engl J Med 1983; 308: 875-878, 934-940.
2. Carrington HC, Crowther AF, Davey DG, Levi AA, Rose FL. A metabolite of 'Paludrine' with high antimalarial activity. Nature 1951; 168: 1080.
3. Canfield CJ, Pudney M, Gutteridge WE. Interactions of atovaquone with other antimalarial drugs against Plasmodium falciparum in vitro. Exp Parasitol 1995; 80: 373-381.
4. Wattanagoon Y, Taylor R, Moody R, Ochekpe N, Looareesuwan S, White N. Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects. Br J Clin Pharmacol 1987; 24: 775-780.
5. Watkins WM, Chulay JD, Sixsmith DG, Spencer HC, Howells RE. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharmacol 1987; 39: 261-265.
6. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990; 30: 593-598.
7. Helsby NA, Edwards IG, Breckenridge AM, Ward SA. The multiple dose pharmacokinetics of proguanil. Br J Clin Pharmacol 1993; 35: 653-656.
8. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism-A panel study. Br J Clin Pharmacol 1991; 31: 689-692.
9. Wright JD, Helsby NA, Ward SA. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides. Br J Clin Pharmacol 1995; 39: 441-444.
10. Wedlund PJ, Alasnian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36: 773-780.
11. Nakamura K, Goto F, Ray WA, McAlister CB, Jacqz E. Inter-ethnic differences in generic polymorphism of debrisoquine and mephenytoin hydroxylation in Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38: 402-408.
12. Watkins WM, Mberu EK, Nevill CG, Ward SA, Berckenridge AM, Koech DK. Variability in the metabolism of proguanil to its active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 1990; 84: 492-495.
13. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T. Metabolic disposition of proguanil in 'extensive' and 'poor' metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Indonesian population. Br J Clin Pharmacol 1995; 39: 297-303.
14. Boeckman AJ, Sheiner BL, Beal SL. NONMEM users guide. San Francisco: NONMEM project Group, University of California, 1992.
15. Proguanil (hydrochloride). Ed Dollery, CT. Therapeutic Drugs, Churchill Livingstone 1991: 247-251.